Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.56 |
| ▸ | JAK1 | P23458 | 4/20 | 0.56 |
| ▸ | KIT | P10721 | 4/20 | 0.56 |
| ▸ | AKT2 | P31751 | 2/20 | 0.54 |
| ▸ | BTK | Q06187 | 4/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 3/20 | 0.50 |
| ▸ | TEC | P42680 | 1/20 | 0.47 |
| ▸ | TXK | P42681 | 1/20 | 0.47 |
| ▸ | BMX | P51813 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1049144 | 1.00 | JAK2 (0.56) | JAK2JAK1KITAKT2BTK | |
| SCHEMBL12957998 | 1.00 | JAK2 (0.56) | JAK2JAK1KITAKT2BTK | |
| SCHEMBL1049106 | 0.88 | KIT (0.53) | JAK2JAK1KITAKT2JAK3 | |
| SCHEMBL1050058 | 0.88 | KIT (0.55) | JAK2JAK1KITAKT2JAK3 | |
| SCHEMBL10320018 | 0.88 | KIT (0.55) | JAK2JAK1KITAKT2JAK3 | |
| SCHEMBL10321504 | 0.88 | KIT (0.53) | JAK2JAK1KITAKT2JAK3 | |
| SCHEMBL1050199 | 0.87 | KIT (0.58) | JAK2JAK1KITAKT2BTK | |
| SCHEMBL10319616 | 0.87 | KIT (0.58) | JAK2JAK1KITAKT2BTK | |
| SCHEMBL10321016 | 0.86 | KIT (0.65) | JAK2KITAKT2BTKJAK3 | |
| SCHEMBL1047833 | 0.86 | KIT (0.65) | JAK2KITAKT2BTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | disclosed |
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885KIT 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.